48,790
edits
Difference between revisions of "Quality"
Jump to navigation
Jump to search
→Immunohistochemistry
(more) |
|||
| Line 147: | Line 147: | ||
{{Main|Immunohistochemistry}} | {{Main|Immunohistochemistry}} | ||
Work-up of suspected IHC problems | ===Classification of IHC tests=== | ||
IHC tests are classified in a paper by Torlakovic ''et al.'':<ref name=pmid20154273>{{Cite journal | last1 = Torlakovic | first1 = EE. | last2 = Riddell | first2 = R. | last3 = Banerjee | first3 = D. | last4 = El-Zimaity | first4 = H. | last5 = Pilavdzic | first5 = D. | last6 = Dawe | first6 = P. | last7 = Magliocco | first7 = A. | last8 = Barnes | first8 = P. | last9 = Berendt | first9 = R. | title = Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. | journal = Am J Clin Pathol | volume = 133 | issue = 3 | pages = 354-65 | month = Mar | year = 2010 | doi = 10.1309/AJCPDYZ1XMF4HJWK | PMID = 20154273 }}</ref> | |||
*''Class I'': | |||
**Adjunct to histomorphology. | |||
**Examples: CD45, S-100. | |||
*''Class II'': | |||
**Considered independent of the other information in the pathology report; thus, cannot be derived from other information in the report. | |||
**Used directly for treatment decisions. | |||
**Examples: ER, PR, HER2. | |||
The implication of irregularies in the different classes are different. Problems in ''Class II'' tests are potentially more severe, as there is no internal control. | |||
===Work-up of suspected IHC problems=== | |||
*Review controls (internal and external). | *Review controls (internal and external). | ||
**Isolated to case vs. larger problem? | **Isolated to case vs. larger problem? | ||
| Line 167: | Line 179: | ||
Notes: | Notes: | ||
*Problems can arise at any step. | *Problems can arise at any step. | ||
==Other== | ==Other== | ||